title: Pancreas preservation with the University of Wisconsin versus Celsior solutions.
abstract: BACKGROUND
  The use of Celsior solution for organ preservation has not been thoroughly studied in pancreas transplantation. The aim of this study was to compare University of Wisconsin and Celsior solutions for preservation of pancreas grafts.
  
  
  METHODS
  From March 1995 to December 2005, 72 patients with type 1 diabetes underwent pancreas transplantation. There were 42 men and 30 women, with a mean age at transplantation of 38.1 +/- 7.5 years (range: 27 to 55 years), and a mean duration of diabetes of 22.5 +/- 6.6 years. Recipients were classified into two groups according to the preservation solution: (A) Celsior (n = 28, 38.9%) and (B) Wisconsin (n = 44, 61.1%).
  
  
  RESULTS
  The donor and recipient characteristics were similar in both groups. There were five cases of venous thrombosis in the Wisconsin group and two in the Celsior group (P = NS). The venous drainage technique in the former group was portocaval in 19 patients and portoiliac in 25; in the Celsior group, portocaval in 23 patients and portoiliac in five (P = .001). Enteric drainage was used in 19 patients from the Celsior group and 17 patients from the Wisconsin group (P = .01). Actuarial 2-year graft survival was 74.6% in the Wisconsin group and 77.4% in the Celsior group (P = NS).
  
  
  CONCLUSIONS
  No differences were observed in venous thrombosis between the two groups. The lower rate of venous thrombosis with the portocaval technique was related to the type of venous drainage rather than the type of preservation solution. Celsior solution may be considered as good as Wisconsin solution for pancreas transplantation.
authors.affiliation: Servicio de Cirugía General, Ap Digestivo y Trasplante de Organos Abdominales, Hospital Universitario Doce de Octubre, Madrid, Spain. ammunicio@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Manrique
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: M L
authors.initials: ML
authors.lastname: Herrero
authors.forename: J C
authors.initials: JC
authors.lastname: Meneu
authors.forename: M
authors.initials: M
authors.lastname: Abradelo
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: E
authors.initials: E
authors.lastname: González
authors.forename: E
authors.initials: E
authors.lastname: Hernández
authors.forename: J M
authors.initials: JM
authors.lastname: Morales
authors.forename: A
authors.initials: A
authors.lastname: Andrés
authors.forename: J
authors.initials: J
authors.lastname: Cortina
authors.forename: E
authors.initials: E
authors.lastname: Moreno
mesh_terms: D000241:Adenosine; D000293:Adolescent; D000328:Adult; D000493:Allopurinol; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D004187:Disaccharides; D004322:Drainage; D004573:Electrolytes; D005260:Female; D005971:Glutamates; D005978:Glutathione; D006639:Histidine; D006801:Humans; D007328:Insulin; D008297:Male; D008353:Mannitol; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions; D010179:Pancreas; D016035:Pancreas Transplantation; D011167:Portacaval Shunt, Surgical; D011887:Raffinose; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data
chemical_list: C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose